{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:19:07Z","timestamp":1764919147407,"version":"3.46.0"},"reference-count":51,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjod"],"DOI":"10.4274\/tjod.galenos.2025.02697","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:50:23Z","timestamp":1760536223000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of asprosin immunoreactivity in endometrial hyperplasia and grade-1 endometrial adenocarcinoma: A retrospective case-control study"],"prefix":"10.4274","author":[{"given":"Ahmet","family":"\u015eenocak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeyda","family":"Yavuzk\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remzi","family":"At\u0131lgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Yurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilal","family":"Balta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"Han\u00e7er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuncay","family":"Kulo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eehmus","family":"Pala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fcnyamin","family":"\u00c7im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/AOG.0000000000001071","article-title":"631: endometrial intraepithelial neoplasia","volume":"126","author":"Parkash","year":"2015","unstructured":"1. Parkash V, Fadare O, Tornos C, McCluggage WG. Committee opinion no. 631: endometrial intraepithelial neoplasia. Obstet Gynecol. 2015;126:897.","journal-title":"Obstet Gynecol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/modpathol.3880051","article-title":"Theories of endometrial carcinogenesis: a multidisciplinary approach","volume":"13","author":"Sherman","year":"2000","unstructured":"2. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308.","journal-title":"Mod Pathol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/cob.12168","article-title":"Development of endometrioid adenocarcinoma despite Levo-norgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG\/BSGE Guideline on the Management of Endometrial Hyperplasia","volume":"7","author":"der Meer AC","year":"2017","unstructured":"3. van der Meer AC, Hanna LS. Development of endometrioid adenocarcinoma despite Levo-norgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG\/BSGE Guideline on the Management of Endometrial Hyperplasia. Clin Obes. 2017;7:54-7.","journal-title":"Clin Obes"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0034-1396256","article-title":"New WHO classification of endometrial hyperplasias","volume":"75","author":"Emons","year":"2015","unstructured":"4. Emons G, Beckmann MW, Schmidt D, Mallmann P; Uterus commission of the Gynecologi-cal Oncology Working Group (AGO). New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015;75:135-6.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/ijc.27457","article-title":"Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan","volume":"131","author":"JV Jr","year":"2012","unstructured":"5. Lacey JV Jr, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer. 2012;131:1921-9.","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","unstructured":"6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025;388:e080978.","DOI":"10.1136\/bmj-2024-080978"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","unstructured":"8. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cncr.34586","article-title":"Annual report to the nation on the status of cancer: this latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Pre-vention, the National Cancer Institute, and the North American Association of Central Can-cer Registries, shows that cancer mortality rates have accelerated, and incidence rates re-main stable, with pancreatic cancer showing an increase in both incidence and mortality: this latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries, shows that cancer mortality rates have accelerated, and inci-dence rates remain stable, with pancreatic cancer showing an increase in both incidence and mortality","volume":"129","author":"Nierengarten","year":"2023","unstructured":"9. Nierengarten MB. Annual report to the nation on the status of cancer: this latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Pre-vention, the National Cancer Institute, and the North American Association of Central Can-cer Registries, shows that cancer mortality rates have accelerated, and incidence rates re-main stable, with pancreatic cancer showing an increase in both incidence and mortality: this latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries, shows that cancer mortality rates have accelerated, and inci-dence rates remain stable, with pancreatic cancer showing an increase in both incidence and mortality. Cancer. 2023;129:8.","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1055-9965.EPI-18-0264","article-title":"Cancer progress and priorities: uterine cancer","volume":"27","author":"AS","year":"2018","unstructured":"10. Felix AS, Brinton LA. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Bi-omarkers Prev. 2018;27:985-94.","journal-title":"Cancer Epidemiol Bi-omarkers Prev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978-2013","volume":"110","author":"Lortet-Tieulent","year":"2018","unstructured":"11. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-61.","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.2147\/CMAR.S199597","article-title":"The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis","volume":"11","author":"Lin","year":"2019","unstructured":"12. Lin TC. The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis. Cancer Manag Res. 2019;11:3481-91.","journal-title":"Cancer Manag Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.trecan.2018.03.004","article-title":"Cancer as a matter of fat: the crosstalk between adipose tissue and tumors","volume":"4","author":"Lengyel","year":"2018","unstructured":"13. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer. 2018;4:374-84.","journal-title":"Trends Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"101855","DOI":"10.1016\/j.tice.2022.101855","article-title":"Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages","volume":"77","author":"Akkus","year":"2022","unstructured":"14. Akkus G, Koyuturk LC, Yilmaz M, Hancer S, Ozercan IH, Kuloglu T. Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages. Tissue Cell. 2022;77:101855.","journal-title":"Tissue Cell"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","article-title":"Asprosin, a fasting-induced glucogenic protein hormone","volume":"165","author":"Romere","year":"2016","unstructured":"15. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566-79.","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","article-title":"Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation","volume":"486","author":"Lee","year":"2019","unstructured":"16. Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96-104.","journal-title":"Mol Cell Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3892\/ol.2021.12911","article-title":"A pancancer over-view of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer","volume":"22","author":"Kerslake","year":"2021","unstructured":"17. Kerslake R, Hall M, Vagnarelli P, Jeyaneethi J, Randeva HS, Pados G, et al. A pancancer over-view of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncol Lett. 2021;22:650.","journal-title":"Oncol Lett"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Yal\u00e7\u0131n E, Pala \u015e, At\u0131lgan R, Kulo\u011flu T, \u00d6nalan E, Arta\u015f G, et al. Is there any difference be-tween endometrial hyperplasia and endometrial carcinoma in terms of expression of TRPM2 and TRPM7 ion channels? Turk J Med Sci. 2019;49:653-60.","DOI":"10.3906\/sag-1810-176"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106979","DOI":"10.1016\/j.ymgme.2022.106979","article-title":"Fibrillin-1 and asprosin, novel players in metabolic syndrome","volume":"138","author":"Summers","year":"2023","unstructured":"19. Summers KM, Bush SJ, Davis MR, Hume DA, Keshvari S, West JA. Fibrillin-1 and asprosin, novel players in metabolic syndrome. Mol Genet Metab. 2023;138:106979.","journal-title":"Mol Genet Metab"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09513590.2018.1512967","article-title":"Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome","volume":"35","author":"Alan","year":"2019","unstructured":"20. Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35:220-3.","journal-title":"Gynecol Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1038\/s41598-019-42061-9","article-title":"The serum level of irisin, but not aspros-in, is abnormal in polycystic ovary syndrome patients","volume":"9","author":"Chang","year":"2019","unstructured":"21. Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK. The serum level of irisin, but not aspros-in, is abnormal in polycystic ovary syndrome patients. Sci Rep. 2019;9:6447.","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"170132","DOI":"10.1016\/j.peptides.2019.170132","article-title":"Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus","volume":"120","author":"Baykus","year":"2019","unstructured":"22. Baykus Y, Yavuzkir S, Ustebay S, Ugur K, Deniz R, Aydin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. Peptides. 2019;120:170132.","journal-title":"Peptides"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.placenta.2020.02.004","article-title":"Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study","volume":"93","author":"Zhong","year":"2020","unstructured":"23. Zhong L, Long Y, Wang S, Lian R, Deng L, Ye Z, et al. Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study. Placenta. 2020;93:17-22.","journal-title":"Placenta"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.numecd.2008.10.010","article-title":"From chronic overnutri-tion to insulin resistance: the role of fat-storing capacity and inflammation","volume":"19","author":"Lionetti","year":"2009","unstructured":"24. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta A. From chronic overnutri-tion to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis. 2009;19:146-52.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-019-6491-6","article-title":"Hydrogen inhibits endometrial cancer growth via a ROS\/NLRP3\/caspase-1\/GSDMD-mediated pyroptotic pathway","volume":"20","author":"Yang","year":"2020","unstructured":"25. Yang Y, Liu PY, Bao W, Chen SJ, Wu FS, Zhu PY. Hydrogen inhibits endometrial cancer growth via a ROS\/NLRP3\/caspase-1\/GSDMD-mediated pyroptotic pathway. BMC Cancer. 2020;20:28.","journal-title":"BMC Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers13153689","article-title":"Statistical meta-analysis of risk factors for endometrial cancer and development of a risk prediction model using an ar-tificial neural network algorithm","volume":"13","author":"Hutt","year":"2021","unstructured":"26. Hutt S, Mihaies D, Karteris E, Michael A, Payne AM, Chatterjee J. Statistical meta-analysis of risk factors for endometrial cancer and development of a risk prediction model using an ar-tificial neural network algorithm. Cancers (Basel). 2021;13:3689.","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.3390\/jcm11195942","article-title":"Differential regulation of genes by the glucogenic hormone asprosin in ovarian cancer","volume":"11","author":"Kerslake","year":"2022","unstructured":"27. Kerslake R, Sisu C, Panfilov S, Hall M, Khan N, Jeyaneethi J, et al. Differential regulation of genes by the glucogenic hormone asprosin in ovarian cancer. J Clin Med. 2022;11:5942.","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/10520295.2022.2135763","article-title":"Use of aspros-in and subfatin for differential diagnosis of serous ovarian tumors","volume":"98","author":"Mirzaoglu","year":"2023","unstructured":"28. Mirzaoglu M, Yavuzkir S, Mirzaoglu C, Yurt N, Dagli AF, Ozcan Yildirim S, et al. Use of aspros-in and subfatin for differential diagnosis of serous ovarian tumors. Biotech Histochem. 2023;98:140-6.","journal-title":"Biotech Histochem"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jnci\/djab191","article-title":"A serum marker for early pancre-atic cancer with a possible link to diabetes","volume":"114","author":"Nam","year":"2022","unstructured":"29. Nam H, Hong SS, Jung KH, Kang S, Park MS, Kang S, et al. A serum marker for early pancre-atic cancer with a possible link to diabetes. J Natl Cancer Inst. 2022;114:228-34.","journal-title":"J Natl Cancer Inst"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"154432","DOI":"10.1016\/j.prp.2023.154432","article-title":"Asprosin, irisin, and meteorin-like protein immunoreactivity in different stages of colorectal adenocarcinoma","volume":"245","author":"Uzun","year":"2023","unstructured":"30. Uzun M, Ilhan YS, Bozdag A, Yilmaz M, Artas G, Kuloglu T. Asprosin, irisin, and meteorin-like protein immunoreactivity in different stages of colorectal adenocarcinoma. Pathol Res Pract. 2023;245:154432.","journal-title":"Pathol Res Pract"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.3934\/mbe.2022251","article-title":"An integrative prognostic and immune analysis of PTPRD in cancer","volume":"19","author":"Ou","year":"2022","unstructured":"31. Ou C, Peng Q, Zeng C. An integrative prognostic and immune analysis of PTPRD in cancer. Math Biosci Eng. 2022;19:5361-79.","journal-title":"Math Biosci Eng"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/cam4.1445","article-title":"Genetic overlap be-tween endometriosis and endometrial cancer: evidence from cross-disease genetic correla-tion and GWAS meta-analyses","volume":"7","author":"Painter","year":"2018","unstructured":"32. Painter JN, O'Mara TA, Morris AP, Cheng THT, Gorman M, Martin L, et al. Genetic overlap be-tween endometriosis and endometrial cancer: evidence from cross-disease genetic correla-tion and GWAS meta-analyses. Cancer Med. 2018;7:1978-87.","journal-title":"Cancer Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"33. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.","journal-title":"CA Cancer J Clin"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/cancers16030582","article-title":"In silico and in vitro mapping of receptor-type protein tyrosine phosphatase receptor type D in health and dis-ease: implications for asprosin signalling in endometrial cancer and neuroblastoma","volume":"16","author":"Orton","year":"2024","unstructured":"34. Orton S, Karkia R, Mustafov D, Gharanei S, Braoudaki M, Filipe A, et al. In silico and in vitro mapping of receptor-type protein tyrosine phosphatase receptor type D in health and dis-ease: implications for asprosin signalling in endometrial cancer and neuroblastoma. Can-cers (Basel). 2024;16:582.","journal-title":"Can-cers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1073\/pnas.1401952111","article-title":"Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis","volume":"111","author":"Ortiz","year":"2014","unstructured":"35. Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, et al. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci U S A. 2014;111:8149-54.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1038\/onc.2010.342","article-title":"The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma","volume":"29","author":"Bralten","year":"2010","unstructured":"36. Bralten LB, Gravendeel AM, Kloosterhof NK, Sacchetti A, Vrijenhoek T, Veltman JA, et al. The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Onco-gene. 2010;29:6138-48.","journal-title":"Onco-gene"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s13046-019-1469-4","article-title":"PTPRD-inactivation-induced CXCL8 promotes an-giogenesis and metastasis in gastric cancer and is inhibited by metformin","volume":"38","author":"Bae","year":"2019","unstructured":"37. Bae WJ, Ahn JM, Byeon HE, Kim S, Lee D. PTPRD-inactivation-induced CXCL8 promotes an-giogenesis and metastasis in gastric cancer and is inhibited by metformin. J Exp Clin Can-cer Res. 2019;38:484.","journal-title":"J Exp Clin Can-cer Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3892\/etm.2011.231","article-title":"Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44","volume":"2","author":"Funato","year":"2011","unstructured":"38. Funato K, Yamazumi Y, Oda T, Akiyama T. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med. 2011;2:457-63.","journal-title":"Exp Ther Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/gcc.20746","article-title":"A catalog of genes homo-zygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene","volume":"49","author":"Kohno","year":"2010","unstructured":"39. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, et al. A catalog of genes homo-zygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49:342-52.","journal-title":"Genes Chromosomes Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.bjc.6603597","article-title":"Stat3 activation in hu-man endometrial and cervical cancers","volume":"96","author":"Chen","year":"2007","unstructured":"40. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, et al. Stat3 activation in hu-man endometrial and cervical cancers. Br J Cancer. 2007;96:591-9.","journal-title":"Br J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"991091","DOI":"10.3389\/fimmu.2022.991091","article-title":"PTPRD\/PTPRT mutation as a predic-tive biomarker of immune checkpoint inhibitors across multiple cancer types","volume":"13","author":"Shang","year":"2022","unstructured":"41. Shang X, Zhang W, Zhang X, Yu M, Liu J, Cheng Y, et al. PTPRD\/PTPRT mutation as a predic-tive biomarker of immune checkpoint inhibitors across multiple cancer types. Front Immu-nol. 2022;13:991091.","journal-title":"Front Immu-nol"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23:232-54.","DOI":"10.1093\/humupd\/dmw042"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jmig.2020.10.009","article-title":"Predictive accu-racy of progesterone receptor b in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD insertion","volume":"28","author":"Raffone","year":"2021","unstructured":"43. Raffone A, Travaglino A, Zullo FM, Gencarelli A, Micheli M, Miranda S, et al. Predictive accu-racy of progesterone receptor b in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD insertion. J Minim Invasive Gynecol. 2021;28:1244-53.","journal-title":"J Minim Invasive Gynecol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2006.08.044","article-title":"COX-2 and survivin are overex-pressed and positively correlated in endometrial carcinoma","volume":"104","author":"Erkanli","year":"2007","unstructured":"44. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E. COX-2 and survivin are overex-pressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 2007;104:320-5.","journal-title":"Gynecol Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/jcp.2006.043794","article-title":"Progressive derailment of cell cycle regulators in endometrial carcinogenesis","volume":"61","author":"Horr\u00e9e","year":"2008","unstructured":"45. Horr\u00e9e N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol. 2008;61:36-42.","journal-title":"J Clin Pathol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/PGP.0000000000000535","article-title":"Expression of laminin recep-tor 1 in normal, hyperplastic, and malignant endometrium","volume":"38","author":"Kurdoglu","year":"2019","unstructured":"46. Kurdoglu M, Kucukaydin Z, Kurdoglu Z, Bulut G, Unlu Y, Ozen S. Expression of laminin recep-tor 1 in normal, hyperplastic, and malignant endometrium. Int J Gynecol Pathol. 2019;38:326-34.","journal-title":"Int J Gynecol Pathol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4103\/ijpm.ijpm_631_23","article-title":"Investigation of hyaluronan synthase 2 and CD44 immune reactivity as a biomarker to predict progesterone-resistant endometrial hy-perplasia without atypia: a retrospective case-control study","volume":"67","author":"Boybay","year":"2024","unstructured":"47. Boybay E, Atilgan R, Pala \u015e, Kulo\u011flu T, Arta\u015f G. Investigation of hyaluronan synthase 2 and CD44 immune reactivity as a biomarker to predict progesterone-resistant endometrial hy-perplasia without atypia: a retrospective case-control study. Indian J Pathol Microbiol. 2024;67:747-52.","journal-title":"Indian J Pathol Microbiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5603\/EP.a2020.0059","article-title":"Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin","volume":"72","author":"Gozel","year":"2021","unstructured":"48. Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2021;72:37-43.","journal-title":"Endokrynol Pol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.crphar.2024.100207","article-title":"Metformin's impact on asprosin and FBN1 expression: potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats","volume":"8","author":"Dashtkar","year":"2024","unstructured":"49. Dashtkar A, Karajibani M, Saravani M, Zanganeh R, Fanaei H. Metformin's impact on asprosin and FBN1 expression: potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats. Curr Res Pharmacol Drug Discov. 2024;8:100207.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3390\/molecules30163410","article-title":"Effects of asprosin and role of TLR4 as a biomarker in endometrial cancer","volume":"30","author":"Karkia","year":"2025","unstructured":"50. Karkia R, Sisu C, Saravi S, Kyrou I, Randeva HS, Chatterjee J, et al. Effects of asprosin and role of TLR4 as a biomarker in endometrial cancer. Molecules. 2025;30:3410.","journal-title":"Molecules"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2024.01.007","article-title":"Associations of metformin therapy treatment with endometrial cancer risk and prognosis: a systematic review and meta-analysis","volume":"182","author":"Xie","year":"2024","unstructured":"51. Xie H, Li M, Zheng Y. Associations of metformin therapy treatment with endometrial cancer risk and prognosis: a systematic review and meta-analysis. Gynecol Oncol. 2024;182:15-23.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Turkish Society of Obstetric and Gynecology"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:07Z","timestamp":1764917167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tjoddergisi.org\/articles\/comparison-of-asprosin-immunoreactivity-in-endometrial-hyperplasia-and-grade-1-endometrial-adenocarcinoma-a-retrospective-case-control-study\/doi\/tjod.galenos.2025.02697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":51,"URL":"https:\/\/doi.org\/10.4274\/tjod.galenos.2025.02697","relation":{},"ISSN":["1307-699X","2149-9330"],"issn-type":[{"type":"print","value":"1307-699X"},{"type":"electronic","value":"2149-9330"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}